[{"id":"f227f01a-e7cc-4c3d-a0dd-a64d4890b600","acronym":"","url":"https://clinicaltrials.gov/study/NCT04756726","created_at":"2021-02-16T12:53:54.984Z","updated_at":"2024-07-02T16:35:06.570Z","phase":"Phase 1/2","brief_title":"Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma","source_id_and_acronym":"NCT04756726","lead_sponsor":"C4 Therapeutics, Inc.","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • cemsidomide (CFT7455)"],"overall_status":"Recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 04/27/2021","start_date":" 04/27/2021","primary_txt":" Primary completion: 09/07/2025","primary_completion_date":" 09/07/2025","study_txt":" Completion: 12/07/2025","study_completion_date":" 12/07/2025","last_update_posted":"2024-05-01"},{"id":"c0336778-22a8-4c11-818f-1fc3b1122699","acronym":"NX-2127-001","url":"https://clinicaltrials.gov/study/NCT04830137","created_at":"2021-04-02T11:53:54.216Z","updated_at":"2024-07-02T16:35:30.165Z","phase":"Phase 1","brief_title":"A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies","source_id_and_acronym":"NCT04830137 - NX-2127-001","lead_sponsor":"Nurix Therapeutics, Inc.","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation • BTK C481","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BTK C481"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zelebrudomide (NX-2127)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 05/05/2021","start_date":" 05/05/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-07"}]